Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
91-105 of 4157 results
Syncona, UCLB launch Freeline Therapeutics to develop gene therapies for bleeding disorders
By PBR Staff Writer
UCL Business, the technology-transfer company of University College London, and Syncona have launched Freeline Therapeutics, a biopharmaceutical firm focused on the development and commercialization of gene therapies for bleeding and other debilitating disorders.
Drug Research > Drug Discovery & Development > News
Constellation Pharmaceuticals raises $55m in mezzanine financing
Constellation Pharmaceuticals has completed a $55m mezzanine round of financing.
Drug Research > Drug Discovery & Development > News
Adimab forms antibody discovery collaborations with MD Anderson and Memorial Sloan Kettering
Adimab has formed two independent academic collaborations, one with The University of Texas MD Anderson Cancer Center and the other with Memorial Sloan Kettering.
Drug Research > Drug Discovery & Development > News
BioAtla signs deal with Pfizer to co-develop new antibody therapeutics
By PBR Staff Writer
BioAtla has signed a license and option agreement with Pfizer to advance the development and commercialization of a new class of antibody therapeutics.
Drug Research > Drug Discovery & Development > News
Celgene, AstraZeneca start Fusion clinical development program in immuno-oncology
By PBR Staff Writer
Celgene and AstraZeneca have started the Fusion clinical development program of durvalumab (MEDI4736) to treat hematologic disorders.
Drug Research > Drug Discovery & Development > News
Eli Lilly halts development of potential diabetes treatment
By PBR Staff Writer
Eli Lilly and Company has halted development of a potential diabetes treatment that raised concerns of liver problems.
Drug Research > Drug Discovery & Development > News
Redx Pharma identifies new cancer drug development candidate
By PBR Staff Writer
UK-based Redx Pharma has identified a new drug development candidate with a potential to treat cancers including pancreatic, triple negative breast, and head and neck cancers.
Drug Research > Drug Discovery & Development > News
Pluristem Therapeutics partners with Fukushima Medical University to test radiation therapy
Israel-based biotechnology company Pluristem Therapeutics has signed a Memorandum of Understanding (MOU) with Fukushima Medical University’s Global Medical Science Center, to test its placenta cell derived radiation therapy.
Drug Research > Drug Discovery & Development > News
Scripps Florida scientists create fingerprints for major drug development targets
For the first time, scientists from the Florida campus of The Scripps Research Institute (TSRI) have created detailed “fingerprints” of a class of surface receptors that have proven highly useful for drug development.
Drug Research > Drug Discovery & Development > News
ORIC Pharmaceuticals raises $53m to advance prostate cancer drug development
By PBR Staff Writer
ORIC Pharmaceuticals has raised $53m to support discovery and development of novel therapies for treatment-resistant prostrate cancers.
Drug Research > Drug Discovery & Development > News
Heptares Therapeutics, Pfizer partner for GPCR-focused drug discovery
By PBR Staff Writer
Heptares Therapeutics and Pfizer have signed a drug discovery collaboration agreement, focused on G protein-coupled receptor (GPCR) targets across several therapeutic areas.
Drug Research > Drug Discovery & Development > News
hVIVO raises £20.5m to support portfolio development
By PBR Staff Writer
Life sciences firm hVIVO has conditionally raised £20.5m to support its development portfolio.
Drug Research > Drug Discovery & Development > News
Teva signs licensing deal with Heptares Therapeutics for migraine treatments
By PBR Staff Writer
Teva Pharmaceutical Industries has signed a licensing and drug-discovery agreement to develop novel, small-molecule calcitonin gene-related peptide (CGRP) antagonists discovered by Heptares Therapeutics to treat migraine.
Drug Research > Drug Discovery & Development > News
Allergan collaborates with Rugen Therapeutics to develop ASD and OCD therapies
By PBR Staff Writer
Allergan has collaborated with Rugen Therapeutics to discover and develop new therapies for autism spectrum disorder (ASD) and obsessive compulsive disorder (OCD).
Drug Research > Drug Discovery & Development > News
Kadmon inks deal with Jinghua to develop antibody product candidates in China
Kadmon announced a new collaboration and license agreement with China’s Jinghua Pharmaceutical to discover, develop and commercialize Kadmon’s fully human anti-VEGFR2 and anti-PD-L1 monoclonal antibodies exclusively for Greater China.
Drug Research > Drug Discovery & Development > News
91-105 of 4157 results